Potentially promising biosimilar appears in the pipeline

The U.S. Food and Drug Administration (FDA) has approved Cyltezo (adalimumab-adbm), a biosimilar to Humira (adalimumab), for the treatment of multiple chronic inflammatory diseases, including psoriasis and psoriatic arthritis.

Cyltezo is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. 

Cyltezo is also indicated, alone or in combination with traditional disease-modifying antirheumatic drugs, or DMARDs, for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis.

The biosimilar, which is manufactured by Boehringer Ingelheim Pharmaceuticals, is administered with a pre-filled syringe. The company is also seeking approval for an auto-injector.

Cyltezo is not commercially available at this time due to pending litigation.

Read more about biosimilars.

 


Driving discovery, creating community

For more than 50 years, we’ve been driving efforts to cure psoriatic disease and improve the lives of those affected. But there’s still plenty to do! Learn how you can help our advocacy team shape the laws and policies that affect people with psoriasis and psoriatic arthritis – in your state and across the country. Help us raise funds to support research by joining Team NPF, where you can walk, run, cycle, play bingo or create your own fundraising event. If you or someone you love needs free, personalized support for living a healthier life with psoriatic disease, contact our Patient Navigation Center. And keep the National Psoriasis Foundation going strong by making a donation today. Together, we will find a cure.

Recent Advance Posts

Doctor and patient in the exam room
What does your primary care provider have to do with managing your psoriatic...
People meeting around a table for discussion
Have we developed the tools to turn psoriasis and psoriatic arthritis into...
The Patient Navigation Center helps a woman whose PsA went undiagnosed for...
hands holding signs numbers 1 through 5
Psoriatic arthritis is a complicated disease. Learn something new today.
FDA approval stamp
Clinical trial data show drug may help you achieve clear skin.
Test tubes in a lab
A study of immune cells points to clues on how psoriasis makes a person more...
Man with joint pain
A physical therapist weighs in on the exercises and activities you can do even...
NPF volunteer at a Team NPF Cycle event
When a new doctor finally took a close look at all of Erin Faulhaber’s symptoms...
Advocates visiting Congress
Forced to retire early because of his PsA, former diplomat Stephen Keat...